PATENT CLAIM ANALYSIS

Application Number: 15892229
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["548", "253000"]

Abstract:
Disclosed are novel calcium release-activated calcium (CRAC) channel inhibitors, methods for preparing them, pharmaceutical compositions containing them, and methods of treatment using them. The present disclosure also relates to methods for treating non-small cell lung cancer (NSCLC) with CRAC inhibitors, and to methods for identifying therapeutics for treating and of diagnosing cancer.

Claim (Index 82):
A method of reducing an inflammation in a subject in need thereof comprising administering to the subject an effective amount of a compound N-{6-[5-cyclopropyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]pyridin-3-yl}-3-fluoroisonicotinamide or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 88.0
- Lexical Diversity: 1.58974
- Patent Class: 548.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14539470', '12899416', '15635268', '12899410', '14626522']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8194507961743507
- 35 USC 102 Novelty (BERT): 0.6074773883639892
- Combined Prediction Score: 0.7982534553933146
- Mean Citation Score: 511.481862
- Max Citation Score: 550.60614
- Similarity Product: 503.9170995426893

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test